Literature DB >> 18468749

Albuminuria and dementia in the elderly: a community study.

Joshua I Barzilay1, Annette L Fitzpatrick, Jose Luchsinger, Sevil Yasar, Charles Bernick, Nancy S Jenny, Lewis H Kuller.   

Abstract

BACKGROUND: Dementia is associated with microvascular disease of the retina. In this study, we examine whether cognitive status (normal cognition, mild cognitive impairment, and dementia) is associated with albuminuria, a microvascular disorder of the kidney. STUDY
DESIGN: Cross-sectional analysis. SETTING & PARTICIPANTS: 2,316 participants from the Cardiovascular Health Cognition Study who underwent brain magnetic resonance imaging and testing for albuminuria. PREDICTOR: Doubling of albuminuria. OUTCOME: Dementia defined according to neuropsychological and clinical evaluation. MEASUREMENTS: Multinomial logistic modeling was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of dementia and mild cognitive impairment with doubling of albuminuria compared with the odds with normal cognition.
RESULTS: 283 participants (12.2%) had dementia, 344 (14.9%) had mild cognitive impairment, and 1,689 (72.9%) had normal cognition. Compared with participants with normal cognition, doubling of albuminuria was associated with increased odds of dementia (OR, 1.22; 95% CI, 1.15 to 1.29). Adjustment for prevalent cardiovascular disease and cardiovascular risk factors, lipid levels, C-reactive protein level, estimated glomerular filtration rate, and apolipoprotein E-4 genotype attenuated this association, but it remained statistically significant (OR, 1.12; 95% CI, 1.03 to 1.22). Mild cognitive impairment was associated with albuminuria on unadjusted analysis, but not with adjustment for other factors. LIMITATIONS: Results are cross-sectional; causality cannot be imputed.
CONCLUSIONS: The odds of dementia increased in the presence of albuminuria. These findings suggest a role of shared susceptibility for microvascular disease in the brain and kidney in older adults.

Entities:  

Mesh:

Year:  2008        PMID: 18468749      PMCID: PMC2607238          DOI: 10.1053/j.ajkd.2007.12.044

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  26 in total

1.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

2.  Assessment of cognitive decline in the elderly by informant interview.

Authors:  A F Jorm; A E Korten
Journal:  Br J Psychiatry       Date:  1988-02       Impact factor: 9.319

3.  The Modified Mini-Mental State (3MS) examination.

Authors:  E L Teng; H C Chui
Journal:  J Clin Psychiatry       Date:  1987-08       Impact factor: 4.384

4.  A method for using MR to evaluate the effects of cardiovascular disease on the brain: the cardiovascular health study.

Authors:  R N Bryan; T A Manolio; L D Schertz; C Jungreis; V C Poirier; A D Elster; R A Kronmal
Journal:  AJNR Am J Neuroradiol       Date:  1994-10       Impact factor: 3.825

5.  Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study.

Authors:  L H Kuller; L Shemanski; T Manolio; M Haan; L Fried; N Bryan; G L Burke; R Tracy; R Bhadelia
Journal:  Stroke       Date:  1998-02       Impact factor: 7.914

6.  Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers.

Authors:  H C Chui; J I Victoroff; D Margolin; W Jagust; R Shankle; R Katzman
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

7.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

8.  Structural-functional relationships in diabetic nephropathy.

Authors:  S M Mauer; M W Steffes; E N Ellis; D E Sutherland; D M Brown; F C Goetz
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

9.  White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke.

Authors:  Lewis H Kuller; W T Longstreth; Alice M Arnold; Charles Bernick; R Nick Bryan; Norman J Beauchamp
Journal:  Stroke       Date:  2004-06-03       Impact factor: 7.914

10.  Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.

Authors:  Koon Teo; Salim Yusuf; Peter Sleight; Craig Anderson; Farouk Mookadam; Barbara Ramos; Lutz Hilbrich; Janice Pogue; Helmut Schumacher
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

View more
  49 in total

Review 1.  Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies.

Authors:  Manjula Kurella Tamura; Kristine Yaffe
Journal:  Kidney Int       Date:  2010-09-22       Impact factor: 10.612

2.  Albuminuria and cognitive decline in people with diabetes and normal renal function.

Authors:  Joshua I Barzilay; James F Lovato; Anne M Murray; Jeff Williamson; Faramaz Ismail-Beigi; Diane Karl; Vasilios Papademetriou; Lenore J Launer
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

Review 3.  Dementia and co-occurring chronic conditions: a systematic literature review to identify what is known and where are the gaps in the evidence?

Authors:  Mark B Snowden; Lesley E Steinman; Lucinda L Bryant; Monique M Cherrier; Kurt J Greenlund; Katherine H Leith; Cari Levy; Rebecca G Logsdon; Catherine Copeland; Mia Vogel; Lynda A Anderson; David C Atkins; Janice F Bell; Annette L Fitzpatrick
Journal:  Int J Geriatr Psychiatry       Date:  2017-02-01       Impact factor: 3.485

4.  The kidney disease quality of life cognitive function subscale and cognitive performance in maintenance hemodialysis patients.

Authors:  Eric P Sorensen; Mark J Sarnak; Hocine Tighiouart; Tammy Scott; Lena M Giang; Bethany Kirkpatrick; Kristina Lou; Daniel E Weiner
Journal:  Am J Kidney Dis       Date:  2012-03-15       Impact factor: 8.860

5.  Relationship between longitudinal measures of renal function and onset of dementia in a community cohort of older adults.

Authors:  Ann M O'Hare; Rod Walker; Sebastian Haneuse; Paul K Crane; Wayne C McCormick; James D Bowen; Eric B Larson
Journal:  J Am Geriatr Soc       Date:  2012-12       Impact factor: 5.562

6.  Association of cognitive function with albuminuria and eGFR in the general population.

Authors:  Hanneke Joosten; Gerbrand J Izaks; Joris P J Slaets; Paul E de Jong; Sipke T Visser; Henk J G Bilo; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

7.  Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders.

Authors:  Daniel E Weiner; Keith Bartolomei; Tammy Scott; Lori Lyn Price; John L Griffith; Irwin Rosenberg; Andrew S Levey; Marshal F Folstein; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2008-12-12       Impact factor: 8.860

Review 8.  Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention.

Authors:  David A Drew; Daniel E Weiner; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2019-08-01       Impact factor: 8.860

9.  Chronic kidney disease, creatinine and cognitive functioning.

Authors:  Merrill F Elias; Penelope K Elias; Stephen L Seliger; Sriram S Narsipur; Gregrory A Dore; Michael A Robbins
Journal:  Nephrol Dial Transplant       Date:  2009-03-18       Impact factor: 5.992

10.  Hypertension and mild cognitive impairment.

Authors:  Cristina Sierra; Mónica Doménech; Miguel Camafort; Antonio Coca
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.